Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts


Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Evan Martin Bloch, M.B.Ch.B., M.S.

Headshot of Evan Martin Bloch
  • Associate Director, Transfusion Medicine Division
  • Associate Professor of Pathology

Languages: English, Afrikaans, Spanish



Research Interests

Neglected Infectious diseases; transfusion transmitted infectious; Babesia; Zika more


Dr. Bloch is an Associate Professor in the Department of Pathology at Johns Hopkins University School of Medicine with a joint appointment in International Health at the Johns Hopkins Bloomberg School of Public Health. Dr. Bloch is also the Associate Director of Transfusion Medicine and current Director of Hemapheresis at the Johns Hopkins Hospital.

Dr. Bloch is originally from South Africa where he completed his medical school (University of Cape Town) and clinical training. Following completion of a combined residency in Anatomic and Clinical Pathology (Tufts Medical Center), post-graduate fellowship in Transfusion Medicine (University of California San Francisco/UCSF), and masters of science in Global Health (UCSF) he continued research at Blood Systems Research Institute while teaching at UCSF in Laboratory Medicine and Global Health Sciences.

Dr. Bloch's major research focus is neglected and emerging infectious diseases particularly in the context of blood transfusion safety. Dr. Bloch has drawn on his diverse background to advance a longstanding interest in the interplay between blood transfusion and infectious diseases, particularly in low and low-middle income countries where transfusion-transmitted infection remains a key metric of suboptimal policies and practices. Blood transfusion networks afford invaluable opportunity to study neglected (e.g., Babesia) and emerging infectious diseases (Zika, SARS-CoV2), as donors contribute large volume samples across a diverse geography. Importantly, many —if not most—infectious risks to the blood supply remain neglected (e.g., malaria, bacteria), particularly in low resource settings, whereby research can yield high impact public health intervention. Blood transfusion itself can also be used to contend with emerging pathogens, as illustrated by the use of convalescent plasma to prevent and/or treat COVID-19.

He has a particular interest in babesiosis, a tick-borne parasitic infection that is endemic to parts of the United States (US). Babesia is globally ubiquitous, yet lack of awareness, in part due to historically limited diagnostic tools, has impeded greater recognition of its role in human disease. Dr. Bloch has participated in studies to develop both antibody and molecular tests for detection of Babesia. The studies have also been used to understand the biology of Babesia infection as well as to conduct surveillance outside of the US.

His research is funded by the National Institutes of Health. The author of over 100 peer-reviewed publications, Dr. Bloch is an active member of the International Society of Blood Transfusion, AABB (formerly American Association of Blood Banks), and the FDA Blood Product Advisory Committee. more


  • Associate Director, Transfusion Medicine Division
  • Associate Professor of Pathology

Departments / Divisions



  • MBChB MS; University of Cape Town Medical School (1999)


  • Anatomic and Clinical Pathology; Tufts-New England Medical Center Hospitals (2008)


  • University of California San Francisco School of Medicine (2009)

Board Certifications

  • American Board of Pathology (Anatomic & Clinical Pathology) (2008)
  • American Board of Pathology (Blood Banking/Transfusion Medicine) (2009)

Research & Publications

Research Summary

Primary Focus

  • Epidemiology and intervention trials focused on neglected (e.g. Babesia) and emerging (eg. Zika) infectious disease, specifically in the context of blood transfusion safety
  • Clinical and operational blood safety in low resource settings

Selected Publications

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie EA, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski L, Bailey JA, Tobian AAR. Deployment of convalescent plasma for the prevention and treatment of COVID-1. The Journal of Clinical Investigation 2020. Jun 1;130(6):2757-2765

Bloch EM, Ness PM, Tobian AAR, Sugarman J. Revisiting Blood Safety Practices Given Emerging Data about Zika Virus. N Engl J Med 2018;378: 1837-41

T Brooks T, Roy-Burman A, Tuholske C, Busch MP, Bakkour S, Stone M, Linnen JM, Gao K, Coleman J, and Bloch EM. Evolution of Zika virus outbreak on Roatán, Honduras: A real-time observation of the epidemic. Emerg Infect Dis 2017;23

Bloch EM, Simon, MS and Shaz, BH. Emerging Infections and Blood Safety in the 21st Century. Ann Intern Med Mar 15 2016

Bloch EM, Lee TH, Krause PJ, Telford SR 3rd, Montalvo L, Chafets D, Usmani-Brown S, Lepore TJ, Busch MP. Development of a real-time polymerase chain reaction assay for sensitive detection and quantitation of Babesia microti infection. Transfusion 2013;53: 2299-306

Activities & Honors


  • AABB (Formerly American Association of Blood Banks)
  • ISBT (International Association of Blood Transfusion)
Is this you? Edit Profile
back to top button